Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan Wade Goldman, Mikhail Vladimirovich Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020
Cited by 688 works. doi:10.1016/s1470-2045(20)30539-8
Authors
- Jonathan Wade Goldman
- Mikhail Vladimirovich Dvorkin
- Yuanbin Chen
- Niels Reinmuth
- Katsuyuki Hotta
- Dmytro V. Trukhin
- Galina Statsenko
- Maximilian Johannes Hochmair
- Mustafa Özgüroğlu
- Jun Ho Ji
- Marina Chiara Garassino
- Олександр Войтко
- Artem Poltoratskiy
- Santiago Ponce
- Francesco Verderame
- Libor Havel
- Igor Bondarenko
- Andrzej Każarnowicz
- György Losonczy
- Nikolay Vladimirov Conev
References
- Discrete Sequential Boundaries for Clinical Trials
- The blockade of immune checkpoints in cancer immunotherapy
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer